US Seeks to Close Gap with China and Australia in Early-Phase Clinical Trials

The FDA and stakeholders are working on a pilot program to speed up early-phase clinical trials in the US. This effort aims to combat the dominance of China and Australia in expediting such trials.

Amgen, a pharmaceutical company, has expressed concerns about potential conflicts of interest in this pilot program. Medical centers, however, seem to be on board with the initiative.

The FDA is trying to address these concerns by ironing out the details of the pilot program. The goal is to make early-phase trials more efficient and competitive with international players.